25 May 2021 | 09:44am
StockMarketWire.com - Mass spectrometry instrument developer Microsaic Systems said it had formed a collaboration with Swansea University Medical School to measure levels environmentally persistent pollutants.
The pair would utilising Microsaic s equipment, to develop a monitoring platform capable of measuring per- and polyfluoroalkyl substances at source and within a laboratory setting. This will be used to establish the health impacts of the broader range of PFAS pollutants, the company said. Through partnership with stakeholders in the environmental sector, this collaboration is designed to better inform pollution remediation, improve management processes for reduced emission and promote safer handling of PFAS chemicals.
Fact check: Has Wales really had the most deaths with Covid-19 in the UK?
We ve looked at the figures being cited suggesting Wales had a higher death rate with coronavirus than any other part of the UK
15:21, 5 MAY 2021
Updated
Sign up to FREE email alerts from
Wales Online -
Subscribe
When you subscribe we will use the information you provide to send you these newsletters. Your information will be used in accordance with ourPrivacy Notice.
Thank you for subscribingWe have more newslettersShow meSee ourprivacy notice Wales has the worst Covid death rate in the UK.
This accusation has been repeated time and again by opponents of Mark Drakeford and Welsh Labour.
Swansea by-election: the candidates for Castle ward
There is a vacant council seat which nine candidates are competing for on May 6
The different faces of Castle ward: flats on Griffith John Street (left), and flats and houses in Swansea Marina (Image: Wales Online / Google Maps)
Want the latest news from Swansea sent straight to your inbox?Invalid EmailSomething went wrong, please try again later.
Don t miss anything from your city! Sign up for regular updates
When you subscribe we will use the information you provide to send you these newsletters. Your information will be used in accordance with ourPrivacy Notice.
Apr 16, 2021
THURSDAY, April 15, 2021 (HealthDay News) The impact of the COVID-19 pandemic and lockdowns on asthma is explored in three studies published online March 29 in
Thorax.
Syed A. Shah, D. Phil., from the University of Edinburgh in the United Kingdom, and colleagues derived asthma exacerbation rates for every week and compared rates for January to August 2020 to a pre-COVID-19 period and January to August 2016 to 2019. Data were included for 100,165 patients with asthma who experienced at least one exacerbation during 2016 to 2020. The researchers found a significant reduction in the level of exacerbation rates across all patients when comparing the prelockdown to postlockdown periods (−0.196 episodes per person-year).
Advancing the Diagnosis and Treatment of Ovarian Cancer
insights from industryDr. Marcos Quintela VasquezResearch and Development Innovation OfficerRBGO Research Group
In this interview, News-Medical talks to Dr. Marcos Quintela Vasquez about the work he is conducting regarding the diagnosis and treatment of ovarian cancer in partnership with CEAT and Porvair Sciences.
Please tell us about CEAT, your project aims and how the group of partners was assembled?
The Cluster for Epigenomic and Antibody Drug Conjugate (ADC) Therapeutics (CEAT) is a Swansea University-led partnership between key multi-national players Glaxo Smith Kline (GSK), Cytiva and Bruker, together with UK-based partners Porvair Sciences Ltd, Axis Bio, and BiVictriX. The CEAT project, jointly funded by the Welsh European Funding Office and collaborating partners, is designed to enable partners to deliver advances in epigenetic and ADC-based ovarian cancer therapeutics.